受注:045-509-1970 |
技術サポート:[email protected] 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
Synonyms | N/A | Storage (From the date of receipt) |
3 years -20°C powder | |
化学式 | C16H19Cl2N5 |
|||
分子量 | 352.26 | CAS No. | 1801747-42-1 | |
Solubility (25°C)* | 体外 | DMSO | 70 mg/mL (198.71 mM) | |
Water | Insoluble | |||
Ethanol | Insoluble | |||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
製品説明 | SHP099 is a highly potent, selective and orally bioavailable small-molecule SHP2 inhibitor with an IC50 value of 71 nM and shows no activity against SHP1. |
---|---|
in vitro | SHP099 is a highly potent, selective and orally bioavailable small-molecule SHP2 inhibitor with an IC50 value of 71 nM |
細胞アッセイ | 細胞株 | Cell-free assays |
---|---|---|
濃度 | 71 nM | |
反応時間 | ||
実験の流れ | ||
動物実験 | 動物モデル | Mice |
投薬量 | 5 mg/kg | |
投与方法 | p.o. |
|
Tyrosine phosphatase SHP2 aggravates tumor progression and glycolysis by dephosphorylating PKM2 in gastric cancer [ MedComm (2020), 2024, 5(4):e527] | PubMed: 38576457 |
SHP2 inhibitors maintain TGFβ signalling through SMURF2 inhibition [ NPJ Precis Oncol, 2023, 7(1):136] | PubMed: 38102334 |
Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy [ Front Immunol, 2023, 14:1260545] | PubMed: 37744352 |
Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy [ Front Immunol, 2023, 14:1260545] | PubMed: 37744352 |
Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC) [ Int J Mol Sci, 2023, 24(13)10545] | PubMed: 37445722 |
Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC) [ Int J Mol Sci, 2023, 24(13)10545] | PubMed: 37445722 |
Early Combined SHP2 Targeting Reverses the Therapeutic Resistance of Vemurafenib in Thyroid Cancer [ J Cancer, 2023, 14(9):1592-1604] | PubMed: 37325052 |
CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors [ Sci Adv, 2023, 9(47):eadg8876] | PubMed: 38000020 |
CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon restoration of RB function in malignant peripheral nerve sheath tumors [ bioRxiv, 2023, 2023.02.02.526674] | PubMed: 36778419 |
Airway epithelial ITGB4 deficiency induces airway remodeling in a mouse model [ J Allergy Clin Immunol, 2022, S0091-6749(22)01342-2] | PubMed: 36243221 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。